JNK3 is abundant in insulin-secreting cells and protects against cytokine-induced apoptosis
- First Online:
- Cite this article as:
- Abdelli, S., Puyal, J., Bielmann, C. et al. Diabetologia (2009) 52: 1871. doi:10.1007/s00125-009-1431-7
- 567 Downloads
In insulin-secreting cells, activation of the c-Jun NH2-terminal kinase (JNK) pathway triggers apoptosis. Whereas JNK1 and JNK2 are ubiquitously produced, JNK3 has been described exclusively in neurons. This report aims to characterise the expression and role in apoptosis of the three JNK isoforms in insulin-secreting cells exposed to cytokines.
Sections of human and mouse pancreases were used for immunohistochemistry studies with isoform-specific anti-JNK antibodies. Human, pig, mouse and rat pancreatic islets were isolated by enzymatic digestion and RNA or protein extracts were prepared. RNA and protein levels were determined by quantitative RT-PCR and western blotting respectively, using JNK-isoform-specific primers and isoform-specific antibodies; activities of the three JNK isoforms were determined by kinase assays following quantitative immunoprecipitation/depletion of JNK3. JNK silencing was performed with small interfering RNAs and apoptotic rates were determined in INS-1E cells by scoring cells displaying pycnotic nuclei.
JNK3 and JNK2 mRNAs are the predominant isoforms expressed in human pancreatic islets. JNK3 is nuclear while JNK2 is also cytoplasmic. In INS-1E cells, JNK3 knockdown increases c-Jun levels and caspase-3 cleavage and sensitises cells to cytokine-induced apoptosis; in contrast, JNK1 or JNK2 knockdown is protective.
In insulin-secreting cells, JNK3 plays an active role in preserving pancreatic beta cell mass from cytokine attacks. The specific localisation of JNK3 in the nucleus, its recruitment by cytokines, and its effects on key transcription factors such as c-Jun, indicate that JNK3 is certainly an important player in the transcriptional control of genes expressed in insulin-secreting cells.
Green fluorescent protein
Human embryonic kidney
c-Jun-NH2-terminal kinase interacting protein
Pancreatic and duodenal homeobox 1
Transcriptional repressor element 1 silencing transcription factor
Small interfering RNA
Apoptosis of insulin-secreting cells is a major event leading to insulin depletion in type 1 diabetes and also contributing to islet transplantation failure [1–4]. The mechanisms leading to apoptosis have been partly deciphered and involve, among other intracellular pathways, p38 mitogen-activated protein kinase , nuclear factor kappa B , signal transducer and activator of transcription 1  and activation of the stress-activated proteins c-Jun NH2-terminal kinases (JNKs) [3, 8]. Three JNK isoforms (JNK1, JNK2 and JNK3) encoded by three distinct genes have been identified ; JNK1 and JNK2 are ubiquitously produced, but JNK3 is essentially restricted to neurons [10, 11]. The role of JNK3 in neuronal excitotoxicity and cerebral ischaemia has been particularly well studied [12–14]; earlier reports indicated that JNK3 was the main pro-apoptotic JNK-isoform in neurons, but more recent data appear to also implicate JNK2 [15, 16].
Insulin-secreting cells and neurons share a number of genes that are predominantly or exclusively expressed in both tissues, e.g. the genes encoding: neuronal cell adhesion molecule, N-cadherin , neuron specific enolase , glutamic acid and glutamate decarboxylase , and islet-brain 1 (IB1) and 2 (IB2) (c-Jun-NH2-terminal kinase interacting protein [JIP] 1 and 2 respectively) [20, 21]. These characteristics probably originate from a common developmental lineage . To date, functional characterisation of the JNK brain-specific isoforms in pancreatic islets has not been performed.
In this study we characterised the expression profile of the three JNK family members in human, pig, mouse and rat pancreatic islets, as well as their sub-cellular localisation and their activities following cytokine treatment. Comparative studies using small interfering RNAs (siRNAs) in rat cell lines were performed to determine the contribution of individual JNK isoforms in cytokine-mediated beta cell death.
Cell and islet culture preparations
Pancreas and islet specimens were prepared from four different deceased human multiorgan donors or from pigs that had been killed. In each case, the purity of human or pig islet preparations was >70%. The human donor’s exemption code from the Institutional Review Board is 0307M50821. Animal experimentation conformed to the Guide for Care and Use of Laboratory Animals, formulated by the National Research Council, 1996, and Swiss law on animal protection, and was authorised by the Veterinarian Office of Canton de Vaud (Lausanne, Switzerland).
Adult male rat (Wistar) pancreases were digested with collagenase solution, the fragmented tissue was washed and collected by centrifugation at 300 g and islets were separated on Ficoll density gradients. Human and pig islets were kindly provided by B. Hering (Diabetes Institute, University of Minnesota, MN, USA) and islet isolation was performed as previously described [3, 8]. Purified islets were cultured for 2 days in CMRL-1066 (Mediatech, Herndon, VA, USA) supplemented with 10% (vol./vol.) fetal bovine serum (Mediatech). The rat insulin-secreting beta cell line (INS-1E) was maintained in RPMI 1640 medium supplemented with 10% (vol./vol.) fetal bovine serum, 10 mmol/l HEPES, pH 7.4, 1 mmol/l sodium pyruvate and 50 μmol/l β-mercaptoethanol in 5% CO2 humidified atmosphere at 37°C.
Cell lysis and western blotting
Cells or fresh tissues were homogenised in cold lysis buffer as described previously [3, 8] and the protein extracts recovered by centrifugation at 20,000 g. Equal quantities of total protein lysates were resolved by SDS-PAGE and electroblotted on to polyvinylidene fluoride membranes. The blots were probed overnight with primary antibodies against: JNK1, p53 (1:500; Santa Cruz Biotechnology, Santa Cruz, CA, USA); and JNK2, JNK3, c-Jun, JunB, phospho-c-Jun or cleaved caspase-3 (1:1,000; Cell Signaling Technology, Danvers, MA, USA). Equal protein loading was determined by blotting membrane against tubulin (1:5,000; Sigma-Aldrich, Buchs, Switzerland). Anti-rabbit or mouse horseradish peroxidase-conjugated secondary antibodies were used to detect protein bands with enhanced chemiluminescence reaction system (Amersham Pharmacia, Biotech Europe, Dübendorf, Switzerland).
Real-time polymerase chain reaction (RT-PCR)
RNA was extracted from tissues or cells using a commercial kit (RNAeasy Mini-kit; Qiagen, Basel, Switzerland) and 1 μg was used for reverse transcription to cDNA with Super script II enzyme (Gibco Invitrogen, Basel, Switzerland). Gene expression was measured by RT-PCR (Light-Cycler PCR System, Roche, Basel, Switzerland) as recommended by the supplier. Quantitative PCR reactions were performed in Master Mix SyBr Green (4 mmol/l; Master Mix; Eurogentec, Liege, Belgium) using 0.5 μmol/l primer mix (Electronic supplementary material [ESM] Table 1) and 2 μl RT product in a total of 20 μl.
Quantitative analysis of mRNA expression using restriction endonucleases
Degenerate primers (ESM Table 1) were designed to amplify the three human JNK mRNAs (JNK1, JNK2, JNK3 [also known as MAPK8, MAPK9 and MAPK10 respectively]) simultaneously and with high efficiency by Light-Cycler. We verified that this set of primers was equally effective in amplifying each JNK isoform by using separate plasmids coding for human JNK1, JNK2 or JNK3 genes in real-time PCRs. PCR products were purified, cloned into pGEM-t Easy Vector (Promega, Wallisellen, Switzerland) and produced by bacterial transformation. We screened 60 positive clones by PCR and determined the distinction between the three isoforms of JNK mRNA by restriction digest. Three endonuclease enzymes (PstI, EcoRV and HindIII) were used to distinguish JNK1, JNK2 and JNK3 cDNAs respectively, on agarose gels.
siRNAs design and cell transfection
Small interfering RNA duplexes against Jnk1, Jnk2, Jnk3  and the green fluorescent protein (GFP) were designed (ESM Table 2) and submitted to BLAST search to ensure their specificity toward the target mRNAs. siRNAs were synthesised by Mycrosynth (Balgach, Switzerland).
Rat INS-1E cells were seeded in six-well plates and incubated overnight in antibiotic-free medium. siRNA duplexes targeting Jnk1, Jnk2 and Jnk3 were mixed with Lipofectamine2000 reagent (10 μg/ml) according to the manufacturer’s instructions (Invitrogen, Basel, Switzerland). siRNA–lipofectamine complexes were added to the cells and incubated for 2 days. Cells were exposed to a cytokine cocktail (R&D Systems, Minneapolis, MN, USA) of rat IL-1β (10 ng/ml), mouse TNFα (25 ng/ml) and rat IFNγ (150 ng/ml) for 24 h.
Immunohistochemical and immunocytochemical staining procedures
Immunohistochemistry was performed on paraffin-embedded adult human and mouse pancreatic sections (5 µm thick) collected on polylysine-coated slides. Paraffin sections were rehydrated, processed for antigen retrieval and pre-incubated with PBS containing 15% (vol./vol.) donkey serum for 1 h.
For immunocytochemistry, INS-1E cells were fixed for 15 min in paraformaldehyde 4% (wt/vol.) on ice and then pre-incubated (0.3% [vol./vol.] Triton X-100, 15% [vol./vol.] donkey serum in PBS) for 1 h. Primary antibodies were incubated overnight at 4°C after dilution in 1.5% (vol./vol.) donkey serum at the following concentrations: 1:100 rabbit anti-JNK3 (Upstate, Lake Placid, NY, USA), 1:50 mouse anti-JNK2 (Santa-Cruz Biotechnology, Santa Cruz, CA, USA) and 1:500 guinea pig anti-insulin (Dako, Carpinteria, CA, USA). After extensive washes in PBS, the sections were incubated for 2 h at room temperature in the appropriate secondary biotinylated donkey anti-mouse or donkey anti-rabbit or donkey anti-guinea pig antibody (Jackson Immunoresearch, West Grove, PA, USA) diluted 1:500 in PBS. The sections were thoroughly rinsed in PBS and incubated for 2 h at room temperature with streptavidin–biotin–peroxidase complex (Vectastain ABC kit, Vector Laboratories, Burlingame, CA, USA). Immunolabelling was revealed after three washes in PBS using 2,3′ diaminobenzidene as substrate diluted 1:10 in buffer according to the manufacturer’s instructions (Roche). Sections were then dehydrated and mounted in Eukitt (O. Kindler, Freiburg, Germany). The specificity of the immunostaining was confirmed by omission of the first antibody or use of preadsorption of primary antibodies with the immunising peptide. Images were acquired by optical microscopy.
Immunoprecipitation and JNK kinase assays
Pre-cleared protein extracts (300 μg) were mixed overnight at 4°C with 1 μg of anti-JNK3 antibody. Protein-G agarose beads (50 μl; Calbiochem, San Diego, CA, USA) were then added for an additional incubation of 4 h. Immobilised protein–antibody complexes were washed three times in cold PBS, collected by centrifugation at 2,000 g and lysed in kinase buffer (20 mmol/l HEPES pH 7.5, 20 mmol/l β-glycerophosphate, 10 mmol/l MgCl2). Supernatant fractions were controlled for potentially remaining JNK3 by western blotting. Isoform-specific JNK activities were determined by in vitro reactions using glutathione S-transferase (GST)–c-Jun (amino acids 1–79) beads mixed to [γ-33P]ATP (Amersham Biosciences, Little Chalfont, UK). The kinase reactions were performed for 30 min at 30°C and stopped by adding SDS sample buffer (100 mmol/l Tris, pH 6.8, 2% [wt/vol.] SDS, 10% [vol./vol.] glycerol, 5% [vol./vol.] 2-β-mercaptoethanol, 0.25% [wt/vol.] bromophenol blue). Phosphorylation of substrate proteins was detected by autoradiography of dried gels (BioMax MS films; Kodak, GE Healthcare, Amersham Biosciences, Little Chalfont, UK).
Apoptosis was determined by scoring cells displaying pycnotic nuclei stained with the DNA-binding dyes Hoechst 33342 (10 μg/ml; Sigma-Aldrich, St Louis, MO, USA) and propidium iodide (5 μg/ml; Sigma-Aldrich, St Louis, MO, USA), as described previously , and visualised under an inverted fluorescence microscope.
All experiments reported were performed a minimum of three times (i.e. n = 3–9 for all data). Data are given as means ± SEM. Statistical analysis of multiple comparisons was determined by one-way ANOVA (post hoc comparisons, Scheffe’s test). The differences found between the experimental groups were considered statistically significant at p < 0.05 or p < 0.01.
JNK3 is highly produced in pancreatic islets
We next examined by western blot analysis the levels of JNK3 in different tissues. The blots revealed that JNK3 occurs in high levels in human and pig islets, but was not detected in either of the whole-pancreas species (Fig. 1c). In the rat, JNK3 production was restricted to the brain and pancreatic islets (Fig. 1d), whereas JNK1 and JNK2 were ubiquitously produced at similar levels in the tissues tested (data not shown).
In insulin-producing cell lines, production of JNK3 was restricted to the rat beta cell line INS-1E; JNK3 was not detected in mouse βTC3 and MIN6 cell lines (Fig. 1e). Antibody specificity was confirmed using protein extracts from human keratinocyte (HaCaT) and human embryonic kidney (HEK)293T cell lines, which do not produce JNK3; protein extracts from mouse or rat brain were used as positive controls for JNK3 detection (Fig. 1e).
Quantitative analysis of JNK1, JNK2 and JNK3 mRNA levels in pancreatic islets
To determine the relative levels of JNK1, JNK2 and JNK3 mRNA in isolated human islets, we used degenerate primers to amplify all three mRNAs simultaneously. We confirmed that this set of primers was equally effective in amplifying each JNK gene separately (data not shown). PCR products were then cloned and analysed by enzymatic digestion to allow discrimination of the respective JNK isoforms. JNK2 and JNK3 isoforms (EcoRV and HindIII fragments, respectively) represented 45% each of the total JNK clones analysed, while 10% of the clones were of JNK1 origin (Fig. 2d). Thus JNK2 and JNK3 represent the two most highly expressed JNK isoforms in human pancreatic islets.
JNK3 is a component of a functional signalling pathway activated by cytokines
JNK3 is nuclear whereas JNK2 is both cytoplasmic and nuclear
Knockdown of JNK3 in INS-1E cells results in higher c-Jun levels
Western blot experiments indicate that JNK3 knockdown increased the protein level of c-Jun; cytokines had a similar, but more pronounced, effect on c-Jun induction (Fig. 5b). Combined JNK3 knockdown and cytokines resulted in an even higher phosphorylation of c-Jun than in each of the separate conditions (Fig. 5c). In contrast, JNK2 knockdown had no detectable effect on levels of c-Jun production in the basal state (Fig. 5b). Both, JNK1 or JNK2 deficiency decreased c-Jun phosphorylation induced by cytokines (Fig. 5c).
Previous studies have shown that the activator protein-1 component JunB is upregulated by cytokines [25, 26]. Cytokines increased JunB levels as expected; JNK1 and to a lesser extent JNK3, but not JNK2 knockdown appeared to decrease cytokine-induced JunB upregulation (Fig. 5c).
JNK3 knockdown increases apoptosis
To determine the role of the different JNK isoforms in cytokine-induced apoptosis, INS-1E cells were transfected with the siRNAs targeting the different JNK genes and were exposed for 24 h to the cytokine cocktail. JNK2 or JNK1 knockdown significantly protected beta cells against cytokine-induced apoptosis and improved beta cell viability by 60 and 40% respectively compared with control siGFP-transfected cells (Fig. 6a). In contrast, JNK3 knockdown strongly enhanced the effect of cytokines on apoptosis. As control, similar results were obtained when using a different siRNA (si3II) against Jnk3  (Fig. 6a). The pro-apoptotic effect of JNK3 knockdown was associated with an increase in caspase-3 cleavage (as evidenced by the appearance of a 19 kDa fragment) at basal or under stress conditions (Cyto-Mix) (Fig. 6b). A similar pattern of cleaved caspace-3 was observed with the second siRNA (si3II) against Jnk3 (data not shown). In contrast, JNK1 or JNK2 knockdown were able to block caspase-3 activation. None of these conditions appeared to affect p53 stability (Fig. 6b).
These data were further sustained by transfecting the siRNAS in βTC-3 cells. Because these cells lack JNK3 (see Fig. 1e), JNK3 knockdown was not expected to have any effect on viability of these cells. Indeed, JNK3 knockdown did not increase apoptosis compared with the siGFP control under cytokine treatments (data not shown).
We describe here the content of JNK3 in pancreatic islets, where it is found at levels similar to those measured in the brain. Our data indicate a protective role of JNK3 against cytokine-induced beta cell death. Whereas knockdown of JNK1 or JNK2 is anti-apoptotic, JNK3 knockdown potentiates cell death in INS-1E cells. Both effects correlate well with the levels of and phosphorylation of c-Jun, which are elevated in the absence of JNK3 and reduced in the absence of the JNK1 or JNK2 isoforms.
The phenotype of JNK3 knockdown is similar to that observed with JunB knockdown, which also increases apoptosis . Interestingly, we observed a JunB decrease in cells lacking JNK3. The question of whether JunB is a major determinant of apoptosis in JNK3-deficient insulin-secreting cells undoubtedly warrants further investigation. However, the situation is further complicated in JNK1 or JNK2 knockdown, where increased levels of JunB correlates with protection (JNK2), but not with JNK1 (decreased apoptosis and decreased JunB levels).
In other cell types including fibroblasts, it has been shown that inactive JNK targets c-Jun to ubiquitination, whereas activation of JNK improves c-Jun stability [27, 28]. Conflicting studies, however, have shown that JNK-mediated phosphorylation of c-Jun accelerates its ubiquitination in T cells [29, 30]. In fibroblasts and in neurons, JNK is usually observed essentially in the cytoplasm, with a fraction of it translocating to the nucleus following activation [31, 32]. We observed very pronounced differences in the intracellular distribution of JNK2 (nuclear and cytoplasmic) vs JNK3, with JNK3 being essentially nuclear. Thus, insulin-secreting cells are clearly distinct from other cell types in that they have high amounts of JNK (JNK3) in the nucleus at basal states.
It is not clear whether the main differences between JNK3 and JNK2 or JNK1 knockdown that we observed are related to the levels of each kinase as such or potentially to the specific intracellular localisation of JNK3 vs JNK2. However, the importance of the intracellular localisation of the different JNK isoforms towards apoptosis has already been addressed [32–34]: in neurons, blockage of nuclear JNKs appears neuroprotective, whereas blocking cytoplasmic JNKs has a strong pro-apoptotic activity [34, 35]. It should, however, be noted that in these experiments, ‘cytoplasmic’ blockade of JNK resulted in depletion from the nucleus of JNKs, which bind to the cytosolic IB1/JIP-1 protein that is exogenously expressed in the cytoplasm (J. Puyal, Department of Cellular Biology and Morphology, University of Lausanne, Lausanne, Switzerland, personal communication). A similar observation had already been made by Dickens, who showed that expression of IB1/JIP-1 ‘traps’ JNK in the cytoplasm, depleting the nuclear compartment . Thus, these and our data indicate that depletion of nuclear JNK is toxic, therefore suggesting that nuclear JNK has a protective role in neurons and insulin-secreting cells.
The effects of JNK3 on apoptosis might be linked to the control of key factors directly contributing to the apoptotic machinery and controlled by c-Jun, such as the Fas-ligand [36, 37] or the gene encoding p53 ; we did not detect any effect of JNK3 knockdown on p53 expression in our conditions. However, the effect might also be indirect. Indeed, the JNK–c-Jun signalling pathway is known to control expression of the insulin promoter by repressing cAMP-induced insulin transcriptional activity . Moreover, pancreatic and duodenal homeobox 1 (PDX-1), an important activator of the insulin promoter, is translocated from the nucleus to the cytoplasm of pancreatic beta cells in response to oxidative stress [40, 41]. Dominant negative forms of JNK inhibit oxidative stress-induced PDX-1 translocation, suggestive of another way by which JNK, and in particular JNK3, might regulate activity of the insulin promoter. Given the known protective role of insulin acting in an autocrine manner on insulin-secreting cells, JNK3 might potentially control apoptosis through the regulation of insulin expression. Indeed, JNK3 knockdown may affect insulin expression (data not shown).
Pancreatic beta cells and neurons share many phenotypic traits such as the expression of neurotrophin receptors  or neuron-specific factors [17–21]. These similarities may be partly explained by the action of a key transcriptional repressor known as ‘transcriptional repressor element 1 silencing transcription factor’ (REST/NRSF). REST acts as a transcriptional repressor that controls the transcription of neuronal genes in non-neuronal tissues, but is not produced in neurons and endocrine pancreas; accordingly, most of its target genes are highly expressed in these two cell types, because they lack REST expression [43–45]. Genes targeted by REST encode neuronal genes expressed in beta cells, such as connexin 36, synaptophysin, secretogranin II and neuronal receptors like glutamate receptor 2 and brain-derived neurotrophin factor , as well as IB1  or IB2  transcription factors and adhesion molecules . The regulatory region of the JNK3 gene contains a potentially functional repressor element-1 that might interact with REST (http://bioinformatics.leeds.ac.uk/group/online/RE1db/re1db_home.htm, accessed 21 May 2009) . These observations are fully consistent with the high level of JNK3 that we found in pancreatic islets.
Altogether, JNK1 or JNK2 vs JNK3 deficiencies exert opposite effects on apoptosis in insulin-secreting cells. The specific localisation of JNK3 in the nucleus, its recruitment by cytokines and its role in downregulating c-Jun levels suggest that JNK3 may play an important role in the transcriptional control of genes expressed in insulin-secreting cells.
We thank F. Maurer for always helpful discussions and a critical reading of the manuscript. This study was supported by grants from the Botnar Foundation and the Swiss National Science Foundation (FNS 320000-118193).
Duality of interest
The authors declare that there is no duality of interest associated with this manuscript.